Nektar Therapeutics (LTS:0UNL)
$ 1.0204 -0.01 (-0.97%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.85 GF Score: 54/100

Nektar Therapeutics to Host Virtual Investor & Analyst Event Transcript

Sep 13, 2023 / 03:00PM GMT
Release Date Price: $0.6511 (-0.23%)
Operator

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Investor and Analyst Event. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Jennifer Ruddock, Chief Business Officer. Please go ahead.

Jennifer Ruddock
Nektar Therapeutics - Chief Business Officer

Thank you, Crystal. Good morning, everyone, and thank you for joining us on today's analyst call to discuss the final Phase 1 data for REZPEG and atopic dermatitis. Next slide.

Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidate REZPEG, clinical trials results,, the timing of the startup and plans for ongoing or planned clinical trials, the therapeutic potential of our drug candidate, the timing and outcome of regulatory decisions and future availability of clinical trial data. Because these statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot